A second phase study of RG2417, an oral form of uridine in patients with bipolar depression, has begun. Patients will take RG2417 or a placebo for six weeks to assess the safety and efficacy of the drug. The first phase of a 6-week study of the RG2133 form of uridine in patients with bipolar disorder and major depression was recently completed.